ALLIANCES AND COLLABORATIONS (Tables)

3 Months Ended

Mar. 31, 2013

Otsuka [Member]

Alliances and Collaborations Statement [Line Items]

Schedule Of Percentage Of Net Sales Recognized From Collaboration [Text Block]

	Share as a % of U.S. Net
	Sales
$0 to $2.7 billion	50%
$2.7 billion to $3.2 billion	20%
$3.2 billion to $3.7 billion	7%
$3.7 billion to $4.0 billion	2%
$4.0 billion to $4.2 billion	1%
In excess of $4.2 billion	20%

Schedule Of Percentage Of Net Sales Payable As Collaboration Fee [Text Block]

	% of Net Sales
	2010 - 2012	2013 - 2020
$0 to $400 million	30%	65%
$400 million to $600 million	5%	12%
$600 million to $800 million	3%	3%
$800 million to $1.0 billion	2%	2%
In excess of $1.0 billion	1%	1%

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended March 31,
Dollars in Millions			2013		2012
Abilify*	net sales, net of amortization of extension payment	$	522	$	621
Oncology Products collaboration fee expense			70		32
Royalty expense			17		17
Reimbursement of operating expenses to/(from) Otsuka			(6)		(24)
Amortization (income)/expense – extension payment			16		16
Amortization (income)/expense – upfront, milestone and other licensing payments			-		2
		March 31,		December 31,
Dollars in Millions		2013		2012
Other assets - extension payment		$	137	$	153

AstraZeneca [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended March 31,
Dollars in Millions		2013		2012
Net sales		$	358	$	161
Profit sharing expense			146		73
Commercialization expense reimbursements to/(from) AstraZeneca			(57)		(12)
Research and development expense reimbursements to/(from) AstraZeneca			(17)		4
Amortization (income)/expense – upfront, milestone and other licensing receipts recognized in:
	Cost of products sold		(75)		-
	Other (income)/expense		(7)		(10)
Upfront, milestone and other licensing receipts:
	Dapagliflozin		80		-
		March 31,		December 31,
Dollars in Millions		2013		2012
Deferred income – upfront, milestone and other licensing receipts
	Amylin-related products	$	3,352	$	3,423
	Saxagliptin		204		208
	Dapagliflozin		203		206

Gilead [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended March 31,
Dollars in Millions	2013		2012
Net sales	$	324	$	322
Equity in net loss of affiliates		4		4

Lilly [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended March 31,
Dollars in Millions	2013		2012
Net sales	$	162	$	179
Distribution fees and royalty expense		67		74
Research and development expense reimbursement to Lilly – necitumumab		-		1
Amortization (income)/expense – upfront, milestone and other licensing payments		9		10
Japan commercialization fee (income)/expense		(4)		(6)
	March 31,		December 31,
Dollars in Millions	2013		2012
Other intangible assets – upfront, milestone and other licensing payments	$	202	$	211

Sanofi [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended March 31,
Dollars in Millions	2013			2012
Net sales	$	137	$	1,900
Royalty expense		2		367
Equity in net income of affiliates		(40)		(60)
Other (income)/expense		(10)		(14)
Noncontrolling interest – pre-tax		24		605
Distributions to Sanofi		-		609
Distributions to BMS		31		67
	March 31,		December 31,
Dollars in Millions	2013		2012
Investment in affiliates – territory covering Europe and Asia	$	18	$	9
Noncontrolling interest		(6)		(30)

Sanofi [Member] | Territory Covering Europe and Asia [Member]

Alliances and Collaborations Statement [Line Items]

Equity Method Investments Disclosure [Text Block]

	Three Months Ended March 31,
Dollars in Millions	2013		2012
Net sales	$	49	$	319
Gross profit		37		138
Net income		36		122

Pfizer [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended March 31,
Dollars in Millions	2013		2012
Net sales	$	22	$	-
Profit sharing expense		10		-
Commercialization expense reimbursement to/(from) Pfizer		(12)		(5)
Research and development reimbursements to/(from) Pfizer		7		2
Amortization (income)/expense – upfront, milestone and other licensing receipts		(10)		(10)
Upfront, milestone and other licensing receipts		125		-
	March 31,		December 31,
Dollars in Millions	2013		2012
Deferred income – upfront, milestone and other licensing receipts	$	512	$	397